Prescient Therapeutics takes cap raise to $9.8m to fast-track cancer treatment
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
While part of the story is an increased ability to diagnose cancers early, thanks to...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.